Data, Discovery, and Defensibility: An Overview of Best Practices for
Pharmaceutical eDiscovery
In today’s digital landscape, data is both an asset and a liability. The sheer scale, variety and velocity of data creation mean that legal teams are now managing evidence that is constantly in motion, generated in emails, chats, cloud drives,
collaboration tools, and mobile devices. In addition, the pharmaceutical industry vast amounts of sensitive data flow daily across research, clinical trials, regulatory filings, and commercial operations often in multiple jurisdictions, each with strict privacy and compliance requirements. As a result, pharmaceutical companies must adopt robust, proactive strategies to manage electronically stored information (ESI) during litigation, investigations, and regulatory reviews. This article outlines key best practices that enable pharma organizations to stay compliant, reduce costs, and protect reputation in the face of increasing discovery challenges
Fill out the form to access content
By submitting this form, you agree to have your contact information passed along for the purpose of following up on your interests and in order to receive communications regarding Integreon products, services, and events. The data sent will be processed in Canada and provided to Integreon who will assume responsibility for processing and Opt-out and Information Removal. For more information, please read our Terms of Use, Privacy, Opt-out & Information Removal below.